Descriptors by number of appropriately timed doses.

<p>Singleton means only one dose was administered; doublet means that two doses were appropriately timed; triplet means that three doses were appropriately timed.</p><p>Bold font signifies significant differences among singleton, doublet and/or triplet doses at p<0.001.</p>*<p>Doses administered at visits at which counseling for smoking cessation, depression, or contraceptive use; and procedures including IUD placement occurred.</p>†<p>Doses administered to Other races than White, Black and Hispanic make up 4% of singleton and doublet doses and were not included in this table.</p

Predictors of Mistimed Doses.

<p>N = 124 mistimed second doses among all doses delivered; N = 153 mistimed third doses among all doses delivered.</p>*<p>Counseling for smoking cessation, depression, or contraceptive use; and Procedures including IUD placement.</p><p>‡adjusted for significant variables in univariate model.</p><p>§Not included in multivariate model due to lack of significance or co-linearity.</p><p>Bold font indicates a significant predictor.</p

Predictors of Appropriately Timed Doublet Dosing.

<p>N = 785 second on-time doses administered.</p>†<p>Adjusted for significant univariate characteristics: visit type and age.</p>*<p>Counseling for smoking cessation, depression, or contraceptive use; and Procedures including IUD placement.</p><p>Bold font values indicate significance.</p

Predictors of On Time Series Completion by Patient-, Clinic- and Systems-Level Characteristics.

*<p>Among women with two or more doses and with complete data. Appropriate dosing interval means: the interval between dose 1 and dose 2≥4 weeks but ≤26 weeks, and the interval between dose 2 and dose 3≥12 weeks, and the interval between dose 1 and dose 3≥24 weeks but ≤52 weeks.</p>§<p>Adjusted for significant variables in the univariate model.</p>§§<p>Variable was not significant in the univariate model.</p>†<p>Visit at which the first dose of HPV4 was initiated.</p><p>Bold font indicates Odds Ratios are statistically significant compared to referent.</p

Clinic- and Systems-Level Characteristics for Each HPV4 Dose.

*<p>Other vaccines given at the same time as HPV4 include TDaP, Td, Hep A, HepA/HepB combination, seasonal flu vaccine, meningitis (MCV4), MMR, pneumococcal vaccine, or varicella virus vaccine.</p>†<p>Birth control includes oral contraceptive pills, OrthoEvra® patch, Nuvaring®, or Depo-Provera® injection.</p>‡<p>Prescriptions include 35 classes of pharmacy dispensed prescriptions in all forms (injectable, oral, suppository, topical, or inhaler) and other vaccines received at the visit, excluding HPV4 vaccination.</p><p>CI means confidence intervals.</p

Descriptors of the Vaccinated Population.

†<p>There were no 9 year olds who received HPV4 in this study. The demographics of the 10–13 year olds were highlighted from the adolescent age group patient-level characteristics because they are a broad CDC target group for HPV vaccination.</p>*<p>Documented at any time prior to the first HPV4 dose.</p

Timely Series Completion by Visit Type at Each HPV4 Dose.

*<p>Dosing intervals: dose 1–2≥4 weeks but ≤26 weeks; dose 2–3≥12 weeks; and dose 1–3≥24 weeks but ≤52 weeks.</p

Descriptors of females receiving care at the Inner City/Urban Core vs. Rural Safety Net Health Care Locations.

<p>^*There are significantly more white females in the rural location than urban, p = 0.026.</p>§<p>There are significantly more black females in the urban location than rural, p = 0.021.</p><p>There are no significant age or pregnancy history differences between the urban core population and the rural population.</p

Females receiving HPV4 by number of doses and Safety Net Health Center Location.

<p>There are no significant differences between the urban core population and the rural population for any dosing scheme.</p><p>Among those at the urban core, significantly more completed two doses on time than three doses on time, 82% vs. 67%, p<0.001.</p

Mistimed HPV4 Doses.

§<p>among those receiving three doses regardless of timing.</p><p>^*among those receiving only two doses regardless of timing.</p><p>Early dosing, overall, occurs significantly more frequently among females receiving HPV4 at urban locations vs. rural locations (p = 0.03).</p